Pharmaceuticals | Free Full-Text | Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.



Pharmacy of Split-Dalmatia County, 21000 Split, Croatia


University Department of Health Studies, University of Split, 21000 Split, Croatia


Department of Toxicology and Pharmacogenetics, School of Medicine, University of Split, 21000 Split, Croatia


Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia


Department of Integrative Physiology, School of Medicine, University of Split, 21000 Split, Croatia


Author to whom correspondence should be addressed.

These authors contributed equally to this work.

Pharmaceuticals 2023, 16(5), 645; (registering DOI)

Received: 28 February 2023
Revised: 21 April 2023
Accepted: 23 April 2023
Published: 25 April 2023


Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH™2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH™2.0 CBD based on polymorphisms in CYP P450 genes and investigate the effects of a single CBD dose on blood pressure. In a randomized and double-blinded order, 12 females and 12 males with reported hypertension were given either placebo capsules or DehydraTECH™2.0 CBD (300 mg of CBD, each). Blood pressure and heart rate were measured during 3 h, and blood and urine samples were collected. In the first 20 min following the dose, there was a greater reduction in diastolic blood pressure (p = 0.025) and mean arterial pressure MAP (p = 0.056) with DehydraTECH™2.0 CBD, which was probably due to its greater CBD bioavailability. In the CYP2C9*2*3 enzyme, subjects with the poor metabolizer (PM) phenotype had higher plasma CBD concentrations. Both CYP2C19*2 (p = 0.037) and CYP2C19*17 (p = 0.022) were negatively associated with urinary CBD levels (beta = −0.489 for CYP2C19*2 and beta = −0.494 for CYP2C19*17). Further research is required to establish the impact of CYP P450 enzymes and the identification of metabolizer phenotype for the optimization of CBD formulations.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *